Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00003560
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 5351
- Registration Number
- NCT00003782
- Locations
- 🇺🇸
Creticos Cancer Center at Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States
🇺🇸Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸CCOP - Virginia Mason Research Center, Seattle, Washington, United States
Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Grupo Oncologico Cooperativo del Sur
- Target Recruit Count
- 42
- Registration Number
- NCT00026078
- Locations
- 🇦🇷
C.R I O., Mar del Plata, Argentina
🇦🇷Centro Oncologico Tres Arroyos, Tres Arroyos, Argentina
🇦🇷Unidad Oncologica Del Neuquen, Neuquen, Argentina
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Aventis Pharmaceuticals
- Registration Number
- NCT00002662
- Locations
- 🇺🇸
George Washington University Medical Center, Washington, District of Columbia, United States
🇺🇸Baptist Regional Cancer Institute - Jacksonville, Jacksonville, Florida, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Arbeitsgemeinschaft fur Internistische Onkologie
- Target Recruit Count
- 300
- Registration Number
- NCT00002544
- Locations
- 🇩🇪
Diakonissen-Krankenhaus Stuttgart, Stuttgart, Germany
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 80
- Registration Number
- NCT00052845
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇨🇦McGill University, Montreal, Quebec, Canada
🇺🇸Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
- Conditions
- Interventions
- Biological: filgrastimDrug: docetaxelDrug: cyclophosphamideGenetic: microarray analysisDrug: epirubicin hydrochlorideDrug: fluorouracilOther: laboratory biomarker analysisOther: immunohistochemistry staining methodProcedure: biopsyProcedure: neoadjuvant therapyProcedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-24
- Target Recruit Count
- 1856
- Registration Number
- NCT00017095
- Locations
- 🇬🇧
Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom
🇵🇹Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A., Lisbon, Portugal
🇨🇭Inselspital Bern, Bern, Switzerland
Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 25
- Registration Number
- NCT00006010
- Locations
- 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 265
- Registration Number
- NCT00024167
- Locations
- 🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸St. Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸University of Mississippi Cancer Clinic, Jackson, Mississippi, United States
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00027859
- Locations
- 🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.